Subscribe

Osimertinib Effective for First-Line Treatment of EGFR Mutation–Positive NSCLC

VBCC - June 2016, Vol 7, No 5 - Lung Cancer
Laura Morgan

The third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (Tagrisso) targets EGFR mutations, including T790M. Osimertinib was approved by the FDA in November 2015 for the treatment of patients with metastatic non–small-cell lung cancer (NSCLC) and the T790M mutation whose disease progressed during or after EGFR TKI therapy.

Now results from a new study indicate that osimertinib is associated with a high overall response rate and prolonged progression-free survival (PFS) in patients receiving osimertinib for the first-line treatment of EGFR mutation-positive NSCLC, according to study results presented at the 2016 European Lung Cancer Conference in Geneva, Switzerland.

“The overall response rate was among the best reported for first-line therapy of EGFR-mutated NSCLC. The progression-free survival results are exciting, well exceeding the historical control rates of 10 to 13 months with first- or second-generation drugs. Many of the patients have not had disease progression on the study and are still benefitting from treatment,” said Suresh Ramalingam, MD, Professor, Emory School of Medicine, Atlanta, GA, and study author.

The study included 60 patients with locally advanced or metastatic EGFR mutation–positive NSCLC who had participated in 2 phase 1 expansion cohorts of the AURA clinical trial. Overall, patients were randomized in a 1:1 ratio to receive osimertinib 80 mg or 160 mg daily, and the median follow-up was 16.6 months.

Impressive Response Rate in First-Line Use

The overall response rate was 77%, with a rate of 67% in patients receiving osimertinib 80 mg and 87% in patients receiving 160 mg. The median PFS was 19.3 months with osimertinib 160 mg and was not yet reached with the 80-mg dose.

The most common adverse events with both doses of osimertinib included diarrhea, stomatitis, and paronychia.

Of note, patients who did have disease progression did not have the T790M mutation as a mechanism of resistance, suggesting that “we may be changing the biology of the disease with the use of first-line osimertinib,” said Dr Ramalingam.

A phase 3 clinical trial confirmatory study will compare osimertinib and erlotinib or gefitinib for first-line treatment of patients with NSCLC.

Related Items
Alemtuzumab Reduces Disability in Patients with Active Relapsing-Remitting Multiple Sclerosis
Laura Morgan
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Multiple Sclerosis
Reducing the Cost and Improving the Care of Patients with Multiple Sclerosis
Laura Morgan
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Multiple Sclerosis
Stem-Cell Therapy Reverses Disability in Multiple Sclerosis
Laura Morgan
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Multiple Sclerosis
Lifestyle Enrichment May Have Some Effect on Alzheimer's Disease Biomarkers
Laura Morgan
VBCN - July 2016 Volume 3, No 2 published on July 25, 2016 in Alzheimer’s Disease/Dementia
Updated NCCN Guideline Calls for EGFR Mutations Testing in All Patients with NSCLC
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Lung Cancer
Approval of First Liquid Biopsy to Detect EGFR Mutations in Lung Cancer Can Improve Patient Outcomes
Jessica Miller
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Lung Cancer
New Migraine Screening Tool Shows Promise
Laura Morgan
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Migraine
BDNF Gene Expression Slows Cognitive Decline in Alzheimer’s Disease
Laura Morgan
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Alzheimer’s Disease/Dementia
Aptiom Improves Quality of Life and Depression in Patients with Partial-Onset Seizures
Laura Morgan
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Epilepsy Update
American Cancer Society Updates Breast Cancer Screening Guidelines for Women at Average Risk
Laura Morgan
VBCC - December 2015, Vol 6, No 11 published on December 16, 2015 in Clinical Guidelines
Last modified: June 24, 2016
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology